Molecular prognostic markers in diffuse large B-cell lymphoma.
| Prognostic Marker . | Effect on Outcome . | Mechanism . |
|---|---|---|
| *Table modified from Lossos9, Gascoyne11 (refer for full list of references) | ||
| Abbreviations: HGAL, human germinal center associated lymphoma; Skp2, s-phase kinase-associated protein 2; ICAM-1, intracellular adhesion molecule-1;, sICAM-1, soluble ICAM-1; sVEGF serum vascular endothelial growth factor; MMP-9, matrix metalloproteinase-9; sIL-10, serum IL-10; MHC, major histocompatibility complex; GCB, germinal center B-cell like; ABC, activated B-cell like | ||
| Bcl-2 | Unfavorable | Anti-apoptosis |
| Bcl-6 | Favorable | Transcriptional repressor |
| CD-10 | Favorable? | Neutral endopeptidase |
| CD-5 | Unfavorable? | B-cell differentiation |
| HGAL | Favorable | Germinal center phenotype |
| FOXP1 | Unfavorable | Transcription factor |
| MUM1 | Unfavorable | Transcription factor |
| Mutation p53 | Unfavorable | Cell cycle regulation |
| Cyclin D2/D3 | Unfavorable | Cell cycle regulation |
| Skp2 | Unfavorable | Cell cycle progression |
| Survivin | Unfavorable | Anti-apoptosis |
| PKC-β | Unfavorable | B-cell signaling |
| CD-21 | Favorable | B-cell differentiation |
| low ICAM-1 | Unfavorable | Lymphocyte trafficking |
| sICAM-1 | Unfavorable | Lymphocyte trafficking |
| Endostatin | Unfavorable | Angiogenesis |
| sVEGF | Unfavorable | Angiogenesis |
| MMP-9 | Unfavorable | Promotes metastases |
| Caspase 8 inhibition | Favorable | Apoptosis signaling |
| Caspase 9 inhibition | Unfavorable | Apoptosis signaling |
| nm23-H1 | Unfavorable | B-cell differentiation |
| sIL-10 | Unfavorable | Immune response regulator |
| loss MHC class II | Unfavorable | Immune surveillance |
| GCB versus ABC | Variable | Molecular subtype |
| Prognostic Marker . | Effect on Outcome . | Mechanism . |
|---|---|---|
| *Table modified from Lossos9, Gascoyne11 (refer for full list of references) | ||
| Abbreviations: HGAL, human germinal center associated lymphoma; Skp2, s-phase kinase-associated protein 2; ICAM-1, intracellular adhesion molecule-1;, sICAM-1, soluble ICAM-1; sVEGF serum vascular endothelial growth factor; MMP-9, matrix metalloproteinase-9; sIL-10, serum IL-10; MHC, major histocompatibility complex; GCB, germinal center B-cell like; ABC, activated B-cell like | ||
| Bcl-2 | Unfavorable | Anti-apoptosis |
| Bcl-6 | Favorable | Transcriptional repressor |
| CD-10 | Favorable? | Neutral endopeptidase |
| CD-5 | Unfavorable? | B-cell differentiation |
| HGAL | Favorable | Germinal center phenotype |
| FOXP1 | Unfavorable | Transcription factor |
| MUM1 | Unfavorable | Transcription factor |
| Mutation p53 | Unfavorable | Cell cycle regulation |
| Cyclin D2/D3 | Unfavorable | Cell cycle regulation |
| Skp2 | Unfavorable | Cell cycle progression |
| Survivin | Unfavorable | Anti-apoptosis |
| PKC-β | Unfavorable | B-cell signaling |
| CD-21 | Favorable | B-cell differentiation |
| low ICAM-1 | Unfavorable | Lymphocyte trafficking |
| sICAM-1 | Unfavorable | Lymphocyte trafficking |
| Endostatin | Unfavorable | Angiogenesis |
| sVEGF | Unfavorable | Angiogenesis |
| MMP-9 | Unfavorable | Promotes metastases |
| Caspase 8 inhibition | Favorable | Apoptosis signaling |
| Caspase 9 inhibition | Unfavorable | Apoptosis signaling |
| nm23-H1 | Unfavorable | B-cell differentiation |
| sIL-10 | Unfavorable | Immune response regulator |
| loss MHC class II | Unfavorable | Immune surveillance |
| GCB versus ABC | Variable | Molecular subtype |